Regen BioPharma Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.83
- Today's High:
- $2.01
- Open Price:
- $1.83
- 52W Low:
- $1.03
- 52W High:
- $12.8173
- Prev. Close:
- $1.82
- Volume:
- 9663
Company Statistics
- Market Cap.:
- $6.15 million
- Book Value:
- -1.487
- Revenue TTM:
- $236560
- Operating Margin TTM:
- -306.75%
- Gross Profit TTM:
- $235517
- Profit Margin:
- 593.3%
- Return on Assets TTM:
- -93.04%
- Return on Equity TTM:
- 0%
Company Profile
Regen BioPharma Inc had its IPO on under the ticker symbol RGBP.
The company operates in the Healthcare sector and Biotechnology industry. Regen BioPharma Inc has a staff strength of 1 employees.
Stock update
Shares of Regen BioPharma Inc opened at $1.83 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.83 - $2.01, and closed at $2.
This is a +9.89% increase from the previous day's closing price.
A total volume of 9,663 shares were traded at the close of the day’s session.
In the last one week, shares of Regen BioPharma Inc have increased by +21.21%.
Regen BioPharma Inc's Key Ratios
Regen BioPharma Inc has a market cap of $6.15 million, indicating a price to book ratio of 0 and a price to sales ratio of 89.7276.
In the last 12-months Regen BioPharma Inc’s revenue was $236560 with a gross profit of $235517 and an EBITDA of $0. The EBITDA ratio measures Regen BioPharma Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Regen BioPharma Inc’s operating margin was -306.75% while its return on assets stood at -93.04% with a return of equity of 0%.
In Q2, Regen BioPharma Inc’s quarterly earnings growth was a negative -45.8% while revenue growth was a positive 0.6%.
Regen BioPharma Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 3.7917
- PEG
- 0
Its diluted EPS in the last 12-months stands at $0.48 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Regen BioPharma Inc’s profitability.
Regen BioPharma Inc stock is trading at a EV to sales ratio of 95.125 and a EV to EBITDA ratio of 8.4436. Its price to sales ratio in the trailing 12-months stood at 89.7276.
Regen BioPharma Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $285196.00
- Total Liabilities
- $5.31 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Regen BioPharma Inc ended 2024 with $285196.00 in total assets and $0 in total liabilities. Its intangible assets were valued at $285196.00 while shareholder equity stood at $-5028973.00.
Regen BioPharma Inc ended 2024 with $0 in deferred long-term liabilities, $5.31 million in other current liabilities, 339.00 in common stock, $-19423836.00 in retained earnings and $0 in goodwill. Its cash balance stood at $692.00 and cash and short-term investments were $692.00. The company’s total short-term debt was $611,590 while long-term debt stood at $0.
Regen BioPharma Inc’s total current assets stands at $62616.00 while long-term investments were $222580.00 and short-term investments were $0. Its net receivables were $56547.00 compared to accounts payable of $29403.00 and inventory worth $0.
In 2024, Regen BioPharma Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Regen BioPharma Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $2
- 52-Week High
- $12.8173
- 52-Week Low
- $1.03
- Analyst Target Price
- $
Regen BioPharma Inc stock is currently trading at $2 per share. It touched a 52-week high of $12.8173 and a 52-week low of $12.8173. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $1.73 and 200-day moving average was $3.18 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 1.5% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About Regen BioPharma Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States. It engages in identifying small molecules that inhibit or express NR2F6 leading to immune cell activation for oncology applications, and immune cell suppression for autoimmune disease. The company is also involved in the development of its products, and therapies, including HemaXellarate, a cellular composition of autologous stromal vascular fraction derived from adipose tissue; dCellVax, an autologous dendritic cell which is treated with an siRNA inhibitor of indoleamine-2,3-dioxygenase; tCellVax which is treated with siRNA to inhibit NR2F6 and the cells re-infused to the patient; DiffronC, uses proprietary siRNA in vivo to inhibit cancer growth and activate T cells; and DuroCAR comprising of CAR-T cells which is treated with an shRNA targeting the gene NR2F6. Regen BioPharma, Inc. was incorporated in 2012 and is based in La Mesa, California.